Regulatory mechanisms of exercise-induced physiological cardiac hypertrophy: progress and prospects

Peng Cheng, Xi Zhang, Yi Si, Qiushi Yin, Chen Lin, Qin Ru, Chong Mow Chu, Huiling Xiang, Ling Liao, Haitao Ran, Zaihong Zhang, Yuxiang WuFrontiers in Cardiovascular Medicine 2025 · DOI

Abstract

Despite its benefits, several challenges remain. Distinguishing PCH from pathological cardiac hypertrophy (PMH) remains difficult, given the limitations of current imaging techniques and biomarkers. Moreover, excessive exercise may precipitate cardiac decompensation, arrhythmias, or dysfunction. Future research should therefore prioritize the development of personalized exercise prescriptions, refinement of diagnostic technologies, and elucidation of the molecular mechanisms driving cardiac decompensation. Such efforts will not only deepen the scientific understanding of exercise-related cardiac remodeling but also provide practical guidance for athlete training and cardiovascular disease prevention.

Introduction: The Clinical "Gray Zone"

Exercise-induced physiological cardiac hypertrophy (PCH), often referred to as the "athlete’s heart," represents a healthy adaptive response to physical activity. However, this adaptation exists in a clinical "gray zone" where it can be difficult to distinguish from pathological cardiac hypertrophy (PMH), such as that caused by hypertension or aortic stenosis. While PCH is reversible and cardioprotective, PMH often leads to fibrosis, heart failure, and sudden death. This paper synthesizes current research to map the molecular and mechanical distinctions between these two states.

Comparison of PCH and PMH across multiple dimensions

Methodology

This systematic review followed PRISMA guidelines, analyzing data from major databases up to August 2025. The synthesis includes human clinical trials utilizing advanced imaging (3D Echocardiography, Cardiac MRI) and mechanistic studies in animal models. The research focuses on three primary regulatory layers: transcriptional, post-transcriptional, and metabolic.

Key Regulatory Mechanisms

The IGF-1/PI3K/Akt Signaling Pathway

A primary "master switch" for PCH is the Insulin-like Growth Factor 1 (IGF-1) axis. Unlike pathological growth triggered by stress hormones (like angiotensin II), PCH is driven by IGF-1 signaling, which promotes protein synthesis and cell survival without inducing the fibrotic response characteristic of disease.

Mechanical Adaptation: Volume vs. Pressure Overload

The heart adapts differently depending on the type of physical stress. Endurance sports (e.g., running, swimming) impose a volume overload, leading to eccentric hypertrophy, characterized by chamber dilation and proportional wall thickening. Conversely, resistance exercise (e.g., weightlifting) imposes a pressure overload, resulting in concentric hypertrophy, where the ventricular walls thicken with minimal change in chamber volume.

PCH induced by different types of exercise

Post-Transcriptional and Metabolic Regulation

Recent insights highlight the role of epitranscriptomics, specifically m6A RNA methylation. Exercise modulates the methyltransferase METTL14, reducing m6A levels on key mRNAs and "unblocking" the IGF-1 pathway. Additionally, circular RNAs like circUtrn act as molecular safeguards, protecting cardiomyocytes from apoptosis during intense stress.

Metabolically, PCH hearts exhibit high flexibility, increasing their capacity for both Fatty Acid Oxidation (FAO) and glucose utilization. This ensures efficient ATP production and prevents the "metabolic starvation" seen in failing hearts.

Clinical Diagnostic Thresholds

Distinguishing PCH from PMH remains a challenge when left ventricular wall thickness (LVWT) falls in the 13–15 mm range. In these cases, clinicians must rely on multimodal assessments:

  • Imaging: 3D Echocardiography and Cardiac MRI are used to assess the Left Ventricular Mass Index (LVMI) and Ejection Fraction (LVEF).
  • Biomarkers: Cardiac troponin (cTn) and B-type natriuretic peptide (BNP) typically peak shortly after exercise and return to baseline within 24–72 hours in healthy athletes. Persistent elevation suggests a transition toward pathology.

Conclusion and Future Directions

While significant progress has been made in identifying the molecular signatures of the athlete's heart, the "tipping point" where healthy adaptation becomes pathological remains elusive. Future research should leverage AI-driven diagnostics to integrate multi-parametric data and develop personalized exercise prescriptions based on individual genetic and biomarker profiles. Understanding the mechanisms of cardiac decompensation will be critical for both athlete safety and the prevention of cardiovascular disease.

Summary updated

Abstract

Despite its benefits, several challenges remain. Distinguishing PCH from pathological cardiac hypertrophy (PMH) remains difficult, given the limitations of current imaging techniques and biomarkers. Moreover, excessive exercise may precipitate cardiac decompensation, arrhythmias, or dysfunction. Future research should therefore prioritize the development of personalized exercise prescriptions, refinement of diagnostic technologies, and elucidation of the molecular mechanisms driving cardiac decompensation. Such efforts will not only deepen the scientific understanding of exercise-related cardiac remodeling but also provide practical guidance for athlete training and cardiovascular disease prevention.
BibTeX
@inproceedings{cheng2025regulatory,
  author = {Peng Cheng and Xi Zhang and Yi Si and Qiushi Yin and Chen Lin and Qin Ru and Chong Mow Chu and Huiling Xiang and Ling Liao and Haitao Ran and Zaihong Zhang and Yuxiang Wu},
  title = {{Regulatory mechanisms of exercise-induced physiological cardiac hypertrophy: progress and prospects}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2025},
  doi = {10.3389/fcvm.2025.1657950},
}
Figure